China’s Draft Ban on Foreign Acquisitions of Biopharma Platforms: What It Means for Licensing Deals
Biotech Deals · Updated October 2026 ·
- Quick answer
- What China actually proposed
- What is not covered: licensing
- Why Beijing is doing this
- Table: 23 largest China licensing deals
- What the table shows
- Implications for dealmakers and investors
- The US side of the equation
- What to watch next
- Source quality and evidence grading
- FAQ
- AI personalization guide
- Sources
Quick answer
Bottom line: On October 16, 2026, China published a draft update to its export blacklist that would ban foreign acquisitions of proprietary cell and gene therapy, siRNA and pathogen gain-of-function platforms, and require approval for full transfers of related target-discovery technologies. Out-licensing is explicitly excluded, which covers nearly every Western deal for Chinese assets so far. Comments close November 15, 2026. The 23 deals in Table 1 total about $13.3 billion in upfront payments, and all are licensing structures, not platform takeovers.
What China actually proposed
According to reporting by Fierce Biotech, Beijing’s Ministry of Commerce proposed an update to its export-control catalogue that covers 40 key technologies, including AI and photovoltaic energy as well as biopharma. Within biopharma, the draft sorts technologies into two tiers.
Tier 1: outright ban on foreign acquisition
Proprietary cell and gene therapy platforms, siRNA platforms and pathogen gain-of-function platforms could not be acquired by foreign buyers. The draft defines a platform as a set of reusable technologies able to support multiple drugs. Chinese officials cited national security for the pathogen component.
Tier 2: restriction requiring approval
Full transfer overseas of proprietary drug-target identification and verification technologies in cell and gene therapy and siRNA would be restricted. A restriction is not a ban. It means a deal needs regulatory sign-off.
Rumors in May had pointed to a longer list that also included multispecific antibodies, antibody-drug conjugates and protein degraders. Those modalities do not appear in the published draft as reported.
What is not covered: licensing
The most important detail for dealmakers is what the draft leaves alone. China’s Ministry of Commerce said out-licensing agreements, and the use of know-how to provide outsourced research and manufacturing services, are outside the ban. Out-licensing of target identification and verification technologies will generally be approved.
Aaron Gu, a partner at Han Kun, summarized the approach as “regulating transfers while leaving licensing unconstrained.” He also called the draft significantly better than market expectations, since the rumored list had raised fears of a sweeping hit to cross-border dealmaking.
This matches how deals have actually been done. Per PharmCube data cited by Fierce, only 5 of 121 cross-border Chinese biopharma out-licensing deals as of July 1 involved an ownership transfer. Foreign buyers have overwhelmingly bought specific drugs or used a platform to find new molecules.
The one deal this would have blocked: AstraZeneca’s roughly $1 billion purchase of Gracell Biotechnologies and its FasTCAR CAR-T platform, announced at the end of 2023 as the first full Big Pharma acquisition of a Chinese biotech. See Fierce Biotech’s coverage.
Why Beijing is doing this
The proposal lands as China has become a leading exporter of biomedicines. China’s drug regulators put foreign transactions of Chinese biotech assets at $120 billion as of August 2026, up 36% year over year.
A senior Chinese biopharma executive told Fierce that the concern is the practice of selling off early-stage assets abroad because many Chinese biotechs lack the cash or experience for late-stage trials and global commercialization. Authorities reportedly do not want a company to build an R&D engine with Chinese resources and then sell the whole company overseas.
Licensing is viewed differently. The licensor keeps ownership, usually retains China rights so Chinese patients still get access, and earns milestones and royalties that bring in foreign exchange. That asymmetry explains why the draft targets ownership transfers and spares licensing.
Table: 23 largest China licensing deals
The table below lists 23 licensing deals ranked by total upfront value, from Pfizer–3SBio at $1.35 billion down to Novartis–Argo at $185 million. Every entry is a licensing arrangement with a Chinese licensor.
| Deal date | Licensee | Licensor | Disease group | Total upfront value ($) |
|---|---|---|---|---|
| 05/19/2025 | Pfizer | 3SBio | Oncology | 1,350,000,000 |
| 10/16/2023 | Novo Nordisk | KBP BioSciences | Cardiovascular, renal | 1,300,000,000 |
| 01/30/2026 | AstraZeneca | CSPC Pharmaceutical | Endocrine, metabolic | 1,200,000,000 |
| 10/21/2025 | Takeda Pharmaceutical | Innovent Biologics | Oncology | 1,200,000,000 |
| 08/09/2024 | Merck & Co. | Curon Biopharmaceutical | Oncology | 700,000,000 |
| 05/28/2026 | Pfizer | Innovent Biologics | Oncology | 650,000,000 |
| 01/12/2026 | AbbVie | RemeGen | Oncology | 650,000,000 |
| 07/14/2026 | AstraZeneca | Dizal Pharmaceutical | Oncology | 600,000,000 |
| 05/12/2026 | Bristol Myers Squibb | Hengrui Pharmaceuticals | Immunology, hematology, oncology | 600,000,000 |
| 11/14/2024 | Merck & Co. | LaNova Medicines | Oncology | 588,000,000 |
| 10/02/2026 | Novartis | Abogen Biosciences | Autoimmune | 575,000,000 |
| 12/06/2022 | Summit Therapeutics | Akeso | Oncology | 515,000,000 |
| 07/27/2025 | GSK | Hengrui Pharmaceuticals | Immunology, oncology, respiratory | 500,000,000 |
| 10/19/2026 | Roche | Hansoh Pharmaceutical | Oncology | 400,000,000 |
| 01/23/2023 | Takeda Pharmaceutical | Hutchmed | Oncology | 400,000,000 |
| 02/08/2026 | Eli Lilly | Innovent Biologics | Immunology, oncology | 350,000,000 |
| 10/24/2023 | Bristol Myers Squibb | LianBio | Cardiovascular | 350,000,000 |
| 09/29/2026 | Novo Nordisk | Hengrui Pharmaceuticals | Metabolic | 300,000,000 |
| 10/29/2024 | GSK | Chimagen Biosciences | Oncology | 300,000,000 |
| 07/08/2026 | AstraZeneca | Sino Biopharmaceutical | Respiratory | 200,000,000 |
| 03/25/2025 | Merck & Co. | Hengrui Pharmaceuticals | Cardiovascular | 200,000,000 |
| 03/24/2025 | Novo Nordisk | The United Laboratories | Endocrine, metabolic | 200,000,000 |
| 01/07/2024 | Novartis | Argo Biopharmaceutical | Cardiovascular | 185,000,000 |
Swipe the table sideways on mobile.
Note: Table 1 is a ranked selection of large deals, not the full market. Figures are total upfront values as compiled; verify against company announcements before citing. Deals dated after October 20, 2026 are not included.
What the table shows
Summing and sorting Table 1 gives the following patterns. These counts describe this 23-deal list only.
- Total upfront value: about $13.3 billion across 23 deals.
- Oncology dominates: 14 of 23 deals involve oncology (about $8.8 billion), including 11 that are oncology only (about $7.4 billion).
- Acceleration: deal count by year runs 1 (2022), 3 (2023), 4 (2024), 5 (2025) and 10 (2026). The 10 deals in 2026 carry about $5.5 billion in upfront value.
- Repeat licensors: Hengrui Pharmaceuticals appears four times (about $1.6 billion) and Innovent Biologics three times (about $2.2 billion), the highest combined upfront total of any licensor.
- Repeat licensees: AstraZeneca (3 deals, $2.0 billion) and Pfizer (2 deals, $2.0 billion) lead by upfront dollars; Novo Nordisk and Merck & Co. each have three deals.
- Beyond oncology: cardiovascular, renal, endocrine and metabolic, respiratory and autoimmune deals show the pattern is broadening beyond cancer.
- Still active: the three most recent entries, Roche–Hansoh (October 19), Novartis–Abogen (October 2) and Novo Nordisk–Hengrui (September 29), show deals continuing as the draft emerged.
Implications for dealmakers and investors
The takeaway is that the rule changes the structure of preferred deals more than their volume. All 23 deals in Table 1 are licensing arrangements, which the draft says it will not constrain.
- Licensing remains the default path. Expect continued option, license and co-development structures with milestone and royalty economics.
- Full acquisitions of platform companies face the biggest risk. Buyers eyeing Chinese cell and gene therapy or siRNA platform owners should assume a ban or approval hurdle if the draft is finalized.
- Diligence now includes export-control scope. Han Kun’s Gu advised foreign buyers to exercise due diligence, noting that before the catalogue is enacted, exports of in-scope technologies must register with the Ministry of Commerce.
- Final text matters. The draft could change after comments close, and the earlier rumored list shows how scope can shift.
Not investment advice. This article summarizes public reporting and a user-compiled deal table for information only.
The US side of the equation
The Chinese draft arrives as US lawmakers push to tighten scrutiny of American purchases of Chinese biotech assets. Representatives John Moolenaar and Debbie Dingell introduced the Biotech Investment National Security Act, though the bill has not advanced in Congress.
Separately, Reuters reported in September that the US Treasury Department is working on rules that would likely preserve American companies’ ability to strike most licensing deals for Chinese drugs. Both governments therefore appear to be converging on tighter control of ownership while leaving licensing largely intact, though neither outcome is final.
What to watch next
- November 15, 2026: close of the public comment period on the draft.
- Final catalogue text: whether multispecifics, ADCs or protein degraders are added back.
- Treasury licensing rules and any movement on the Biotech Investment National Security Act.
- Next licensing announcements: whether deal pace in Table 1 holds after the catalogue is enacted.
Source quality and evidence grading
This is a policy and deal-flow topic, so clinical CEBM levels do not apply directly. We adapt the idea: Tier A is a primary official document, Tier B is official or data-based secondary reporting, and Tier C is expert opinion. Expert opinion is the CEBM equivalent of Level 5 evidence.
| Claim source | Nature of evidence | Grade |
|---|---|---|
| China draft export-control update (MOFCOM) | Primary regulatory document; draft, subject to change | Tier A |
| MOFCOM media Q&A on exclusions | Official clarification, not binding text | Tier B |
| PharmCube and Chinese regulator statistics via Fierce Biotech | Secondary data reporting | Tier B |
| Han Kun partner and Chinese biopharma executive commentary | Expert opinion, interested parties | Tier C |
| Table 1 deal list | Compiled dataset; verify against announcements | Tier B/C |
FAQ
What is China proposing to ban?
China's draft update to its export-control catalogue would block foreign acquisitions of proprietary cell and gene therapy platforms, siRNA platforms and pathogen gain-of-function platforms. A platform here means a reusable set of technologies that can support multiple drugs.
What is the difference between a ban and a restriction in the draft?
A ban blocks the transaction outright. A restriction means the deal is possible but needs regulatory approval. The draft restricts full transfers of proprietary drug-target identification and verification technologies in cell and gene therapy and siRNA to overseas entities.
Does the draft rule stop out-licensing deals with Chinese biotechs?
No. China's Ministry of Commerce said out-licensing agreements and outsourced research and manufacturing services fall outside the ban, and out-licensing of target identification and verification technologies will generally be approved. Most Western deals for Chinese assets to date are licensing structures.
Which past deal would likely have been blocked?
AstraZeneca's roughly $1 billion acquisition of Gracell Biotechnologies, which owned the FasTCAR CAR-T platform, would likely not have been possible under the draft rule.
When is the comment period and is the rule final?
The rule is a draft. The Chinese government is seeking public comments until November 15, 2026. Until the revised catalogue is enacted, exports of in-scope technologies must still register with the Ministry of Commerce.
How much licensing money does the table show?
The 23 deals in Table 1 total about $13.3 billion in upfront payments. Fourteen of them involve oncology, worth about $8.8 billion combined. Ten were signed in 2026 alone, worth about $5.5 billion.
Is this investment advice?
No. This article is for information only. Deal terms, draft rules and political developments change, so verify against primary sources and consult a qualified adviser before making financial decisions.
AI personalization guide
Paste this article, or its URL, into an AI assistant with one of the prompts below to tailor the analysis to your role.
| Claude | “Using this article’s Table 1, explain how the draft China export rule affects a licensing deal for a siRNA asset versus an acquisition of a siRNA platform company. List diligence questions I should ask.” |
| ChatGPT | “Summarize the China draft export-control rule for an investor. Then build a checklist for evaluating a China biotech licensing deal against the ban and restriction categories.” |
| Gemini | “Compare China’s draft biopharma platform rule with the proposed US Biotech Investment National Security Act. What overlaps, and what differs?” |
| Perplexity | “What is the latest status of China’s draft export blacklist for cell and gene therapy and siRNA platforms after November 15, 2026? Cite primary sources.” |
Sources
- China looks to ban foreign acquisitions of critical biopharma platforms, Angus Liu, Fierce Biotech, October 16, 2026.
- China Ministry of Commerce draft export-control update (Chinese).
- Ministry of Commerce media Q&A (Chinese).
- Reuters: US weighs allowing most pharma licensing deals with China, September 18, 2026.
- Table 1: compiled deal dataset; verify against company press releases. Source: Evaluate
Related:
Disclosure: This article is editorial and informational only, not medical, legal or investment advice. It contains no affiliate links. Other One Day Media Network pages may include affiliate links, which are disclosed where they appear.
Comments